Angelini Ventures

Angelini Ventures

Mandanti di venture capital e private equity

Chi siamo

Angelini Ventures is the venture capital arm of Angelini Industries funded with a €300 million capital commitment to build and invest in companies that develop innovative ideas and solutions in biotechnology, digital health and life sciences. Angelini Ventures invests across Europe and North America with a focus on brain health and consumer segments such as women, children and the elderly. The company is headquartered in Rome with a global team spread across Europe, Asia and the US to provide global perspective and capabilities.

Settore
Mandanti di venture capital e private equity
Dimensioni dell’azienda
11-50 dipendenti
Sede principale
Rome
Tipo
Società privata non quotata

Località

Dipendenti presso Angelini Ventures

Aggiornamenti

  • Visualizza la pagina dell’organizzazione di Angelini Ventures, immagine

    7.761 follower

    Today marks an important milestone as the Angelini Industries Group unveils its first #ESG Strategic Plan, and at Angelini Ventures, we're proud to contribute to this transformative sustainability journey. We firmly believe that meaningful innovation in healthcare must embody an inclusive vision where access and equity are foundational principles. This conviction drives our dual commitment: investing in healthcare innovations that enhance equitable access to care, while promoting diversity and inclusion within our teams and portfolio companies. Angelini Industries' ambitious ESG roadmap, spanning People, Patients/Customers/Communities, Ecosystems, and the Planet, closely aligns with our own sustainability priorities. We're deeply engaged in contributing to this Group-wide effort, leveraging our active investor role to promote responsible, sustainable business practices across our portfolio. Read the full news in the press release https://lnkd.in/d6w-PCDB

    Visualizza la pagina dell’organizzazione di Angelini Industries, immagine

    139.759 follower

    🇮🇹 Nell’anno record per ricavi, a 2,1 miliardi di euro (+7,6%), aumenta anche il valore economico generato (+7,5%) da Angelini Industries, che raggiunge i 2,3 miliardi di euro, di cui l’86% distribuito agli stakeholder. È quanto emerge dal Bilancio di Sostenibilità 2023, che misura gli impatti delle attività del Gruppo in ambito ESG. Contestualmente, è stato inoltre annunciato il primo Piano ESG, con obiettivi e target al 2026 e un orizzonte al 2030: focus su Persone, Pazienti Clienti e Comunità, Ecosistemi e Pianeta. Azioni che dimostrano come la sostenibilità sia un driver di crescita per il gruppo e le società operative, le cui performance sono rendicontate nei Bilanci e Profili di Sostenibilità di Angelini Pharma, Angelini Technologies - FAMECCANICA, Angelini Ventures, Angelini Wines & Estates. 👉 Leggi il comunicato stampa: https://lnkd.in/d6_F2MqD 🇬🇧 In a record-breaking year for revenue, which reached 2.1 billion euros (+7.6%), the economic value generated by Angelini Industries also increased (+7.5%) to 2.3 billion euros, of which 86% was distributed to stakeholders. These results are highlighted in the 2023 Sustainability Report, which showcases the Group’s ESG impact. Alongside, Angelini Industries announced its first ESG Plan, with objectives and targets set for 2026 and a timeline to 2030: focus on people, patients, customers, community, ecosystems and planet. These actions demonstrate how sustainability drives growth within the Group and its operating companies, whose performance is reported in the sustainability reports and profiles of Angelini Pharma, Angelini Technologies - FAMECCANICA, Angelini Ventures, and Angelini Wines & Estates. 👉 Read the press release: https://lnkd.in/d6w-PCDB #AngeliniIndustries #IndustryOfCare #SustainabilityReport2023 #PianoESG

    • Nessuna descrizione alternativa per questa immagine
  • Visualizza la pagina dell’organizzazione di Angelini Ventures, immagine

    7.761 follower

    🚀 Attention future VCs and career changers! 🎧 Ever wondered what it takes to break into the world of venture capital? 🤔💼 Our very own Lola Buono spills the tea on her journey from biotech studies to her VC role in the latest episode of "I lavori di domani" Radio 24 podcast with Anna Marino! 🎉 Key takeaways for aspiring VCs: 🔬 Rock a tech/science degree 📚 Dive deep into a specific field 💪 Learn by doing - nothing beats hands-on experience! Pro tip: Check out VC fellowship programs (like ours at Angelini Ventures https://lnkd.in/dvxumPcV) to get your foot in the door while still studying! 🚪🏃♀️ Ready to shape the future of innovation? Don't miss this episode! 🎧✨ https://lnkd.in/dhuJ3Mx3 (Note: Podcast is in Italian 🇮🇹) #VentureCapital #CareerAdvice #podcast Thank you, Angelini Industries and SEC Newgate Italia, for facilitating the development of this insightful content!

    Visualizza la pagina dell’organizzazione di Radio 24, immagine

    6.930 follower

    Per lavorare nel settore della biotecnologia medica è necessaria una formazione scientifica/tecnica, laurea in biotecnologie, biologia, chimica o discipline affini. Ma insieme alle competenze è altrettanto importante la volontà di imparare sul campo, essere coscienti della forte propensione al rischio e la proattività nel cercare le opportunità in fondi di Venture Capital per inserirsi in un settore ancora abbastanza "di nicchia" ma in forte crescita. In questa puntata del podcast I lavori di domani, Anna Marino ne ha parlato con Lola Buono, biotecnologa medica e associate Angelini Ventures, che ha conseguito il dottorato di ricerca in fisiopatologia medica e biotecnologie presso l'Università degli Studi di Torino e condotto ricerche presso il MOLECULAR BIOTECHNOLOGY CENTER di Torino e lo Memorial Sloan Kettering Cancer Center di New York, uno dei principali centri oncologici negli Stati Uniti. Dopo il dottorato, ha iniziato la sua carriera nel venture capital in Claris Ventures, fondo da 85 milioni di euro basato a Torino, che investe in start-up nel settore biotech italiano. Ascolta la puntata de I lavori di domani a questo link: https://lnkd.in/dHup-eqj #Radio24 #podcast #Ilavorididomani #biotech #biotecnologie #medicale #venturecapital #startup

  • Visualizza la pagina dell’organizzazione di Angelini Ventures, immagine

    7.761 follower

    We invite you to watch this insightful video interview from BiotechTV, featuring our Medical Director, Fabrizio Calisti, in conversation with BiotechTV founder Brad Loncar. In this compelling discussion, Fabrizio discusses our current and future strategies to continue shaping the future of care. As concrete examples of these strategies in action, he spotlights two of our portfolio companies that many BiotechTV followers already know and appreciate: Pretzel Therapeutics and Nouscom . We'd like to extend our sincere thanks to Brad for visiting us in Rome and to BiotechTV for their important work in disseminating knowledge in the biotech sector. We're also grateful to MEDiSTRAVA, an Inizio Company for facilitating the connection that made this interview possible. #Biotech #HealthcareInnovation #FutureOfCare

    Visualizza la pagina dell’organizzazione di BiotechTV, immagine

    19.518 follower

    𝐅𝐫𝐨𝐦 𝐑𝐨𝐦𝐞: Backed by a conglomerate that has pharma expertise, Rome based Angelini Ventures has a $300M fund that invests broadly in life sciences and healthcare. Medical Director Fabrizio Calisti describes the fund, its foundation in the CNS but broad interest today, current portfolio holdings, and his take on biotech in the area. Full video: https://lnkd.in/gFSBnNWb BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | Theragent Inc | NYSE | Allucent

  • Visualizza la pagina dell’organizzazione di Angelini Ventures, immagine

    7.761 follower

    One month after our first Angelini Ventures Healthcare Summit, we're excited to share this aftermovie that captures the spirit of innovation and collaboration that defined the event! This video isn't just a celebration of a successful event that brought together 100 key players in healthcare, including investors, experts, portfolio companies, and colleagues from Angelini Industries and Angelini Pharma. It reflects our two-year journey at Angelini Ventures (October 19th marks our official second anniversary! 🎉) and our core belief: innovation thrives on relationships. We extend our heartfelt thanks to all participants, with special gratitude to the speakers who shared their valuable perspectives in this video: thank you Jill Schiaparelli, MBA (Avation Medical), Baruch Harris (Pretzel Therapeutics), Suman Rao, PhD (Lumira Ventures), Shriram Raghunathan, Ph.D (Noctrix Health, Inc.). Here's to many more years of collaborative progress in healthcare! Video credits 🎬: Terroir Films

  • Visualizza la pagina dell’organizzazione di Angelini Ventures, immagine

    7.761 follower

    Just in from Italian Tech Alliance: the latest Quarterly Venture Capital Observatory data paints an exciting picture for Italian (and European) innovation landscape. Prepared with Growth Capital Partners and supported by CDP Venture Capital SGR and Zest Group, the numbers speak volumes. Key highlights: 🔸Q3 2024: €524 million invested, up from €228 million in Q2 🔸First 9 months of 2024: €1.195 billion across 247 rounds - already surpassing all of 2023! 🔸Notable increases in both Series A (13) and Series B (6) rounds Our CEO, Paolo Di Giorgio, joined a panel discussion emphasizing how CVC independence can drive innovation and bridge established businesses with startups. Kudos to Italian Tech Alliance and all participants for these valuable insights. Read the full report here https://lnkd.in/d3ubp3bN What's your take on these trends? Let's keep the conversation going! 

    Visualizza la pagina dell’organizzazione di Italian Tech Alliance, immagine

    14.639 follower

    Abbiamo presentato poco fa i numeri dell'Osservatorio Trimestrale sulle performance del Venture Capital in Italia, come da consuetudine predisposti assieme a Growth Capital e per l’occasione con il supporto di CDP Venture Capital SGR Capital e la partnership di Zest Group. 📊 Gli Highlights: - Nel Q3-2024 sono stati investiti €524 milioni, in aumento rispetto ai €228 milioni investiti nel trimestre precedente - Complessivamente, nei primi nove mesi del 2024, sono stati investiti €1,195 miliardi in 247 round, un valore già superiore all'intero 2023 - I round Serie A aumentano, passando da 10 del trimestre precedente a 13 nel Q3-2024 - Sono cresciuti anche i round Serie B, arrivando a 6 rispetto ai 2 del Q2-2024 Un grazie particolare a Fabio Mondini de Focatiis, che ha presentato i dati sugli investimenti in startup e PMI innovative del terzo trimestre del 2024 e a Laura Morelli, direttrice di Dealflower che ha moderato i tanti ospiti intervenuti ad animare la conversazione: Luigi Capello, CEO di Zest GroupAgostino SCORNAJENCHI, AD di CDP Venture Capital SGR, il nostro presidente Giuseppe Donvito, partner di P101; e i protagonisti del panel di confronto: Alessandro Seina di Radical Storage, Elena Lanati di Lionhealth Società Benefit (SB), Paolo Di Giorgio di Angelini Ventures e Davide Fioranelli di Lumen Ventures. Appuntamento tra soli due giorni, a Reggio Emilia, per approfondire i dati dell’ecosistema emiliano - romagnolo! Per scoprire i dati del Q3: 🇮🇹 https://lnkd.in/dMrPthiX 🇬🇧 https://lnkd.in/d3ubp3bN #Q3 #VC #innovazione #ecosystem

    • Nessuna descrizione alternativa per questa immagine
    • Nessuna descrizione alternativa per questa immagine
    • Nessuna descrizione alternativa per questa immagine
    • Nessuna descrizione alternativa per questa immagine
    • Nessuna descrizione alternativa per questa immagine
  • Visualizza la pagina dell’organizzazione di Angelini Ventures, immagine

    7.761 follower

    New week, new events to attend! On October 17th and 18th, Berlin becomes the epicenter of health innovation at the bcc - Berlin Congress Center, and we're proud to announce that our very own Elia Stupka and Nils Bottler will be attending Frontiers Health 2023! 📅 Mark your calendars for October 17th: 📌 Elia will be participating in the panel "The Path to Scaling Mental and Brain Health Solutions" 📌Nils will be joining the "Start-up and Scale-up Discovery" session number 2 Established in 2015, Frontiers Health is a highly curated event that brings together ecosystem leaders - founders, C-Suite executives, senior government officials, and academic thought leaders - to discuss the next frontier of innovation in health and life sciences. Attending Frontiers Health? Reach out to schedule a meeting with Elia or Nils during the event. Interested in joining us at Frontiers Health? Register now and get 25% off with the code FHSPX25 here: https://lnkd.in/dmdSEa3Q Don't miss this opportunity to be part of shaping the future of healthcare innovation! #FH24 #healthinnovation #Berlin

    • Card with orange background and the photo of Elia Stupka, Managing Director at Angelini Ventures. One of the speakers at Frontiers Health taking place in Berlin on October 17-18. The hashtag #FH24 is hihglihgted in white
    • Card with orange background and the photo of Nils Bottler, Principal at Angelini Ventures. One of the speakers at Frontiers Health taking place in Berlin on October 17-18. The hashtag #FH24 is hihglihgted in white
  • Visualizza la pagina dell’organizzazione di Angelini Ventures, immagine

    7.761 follower

    At Angelini Ventures, we're committed to being where innovation happens. That's why our team - Lola Buono, Thomas Michael Thestrup, and Nils Bottler - attended the recent LSX Nordic Congress in Copenaghen, a key event where life science innovators and investors converged to shape the future of healthcare. A highlight was Nils' participation in the panel "Achieving Patient Centricity, Scale, and Profitability with Digital Therapeutics". Moderated by Valentin Lubbe , the discussion featured insights from industry leaders including John Drakenberg (Alex Therapeutics), Mikaela K Odlander (Orexo AB publ) , and Ann-Kathrin von Knobloch (Weigand) (Flying Health). Here are the key takeaways that caught our attention: 1️⃣ Limited Scale in Reimbursed Space: Digital therapeutics have yet to achieve significant scale in the reimbursed market. While they haven't reached traditional venture success levels, they are laying the groundwork for sustainable businesses. 2️⃣ Platform Consolidation: Emerging platform plays are consolidating the market, creating opportunities for scalable business models. These platforms can unlock value by integrating various digital therapeutic solutions and leveraging economies of scale. 3️⃣ Combination with Traditional Healthcare: The real potential lies in combining digital therapeutics with traditional drugs and healthcare services. This hybrid model offers a larger market, broader acceptance, and established reimbursement, potentially accelerating growth and patient adoption. 4️⃣ Early Days of Digital Therapeutics: Digital therapeutics are still in their early stages, but they hold significant potential to drive efficiency in care delivery. We believe that in the long run, digital therapeutics will succeed and generate robust business models in healthcare. As this dynamic field evolves, Angelini Ventures remains dedicated to fostering innovation at the cutting edge. We're excited to support and drive forward the most promising developments in healthcare technology. #DigitalTherapeutics #HealthcareInnovation #PatientCentricity #FutureOfHealthcare

    • Nessuna descrizione alternativa per questa immagine
    • Nessuna descrizione alternativa per questa immagine
    • Nessuna descrizione alternativa per questa immagine
  • Visualizza la pagina dell’organizzazione di Angelini Ventures, immagine

    7.761 follower

    At Angelini Ventures we emphasize the importance of speaking up about mental health to reduce stigma, encourage help-seeking, and transform access to critical mental health resources. We're inspired by Silvia Wang, CEO and Co-Founder of Serenis, one of our portfolio companies. Serenis is revolutionizing mental wellbeing through its innovative platform, offering online psychotherapy, coaching, counseling, and psychiatry—making professional support more accessible than ever before. We proudly support Serenis, its team and its mission. Their digital approach exemplifies how technology can break down barriers to mental health care, creating a more accessible and supportive environment for all. On this World Mental Health Day, let's commit to continuing this crucial conversation. Together, we can build a world where mental health is prioritized, understood, and accessible to everyone. #WorldMentalHealthDay #BreakTheStigma #MentalHealthAwareness #portfolio

    • Nessuna descrizione alternativa per questa immagine
    • Nessuna descrizione alternativa per questa immagine
    • Nessuna descrizione alternativa per questa immagine
  • Visualizza la pagina dell’organizzazione di Angelini Ventures, immagine

    7.761 follower

    Our London-based colleague Maya Misra represented Angelini Ventures at the Sifted Summit in London this week! Maya's key takeaways from the Summit are inspiring and reflect our forward-thinking approach: 🔹 Diverse Perspectives: The Summit showcased a variety of viewpoints on technology's role in healthcare, emphasizing the critical importance of patient-centric care. 🔹 Pragmatic Insights: Refreshingly, discussions on biotech and digital health were grounded in reality. Instead of hype, the focus was on identifying areas of tangible value. 🔹 Engaging Roundtable: Maya participated in an insightful small-group roundtable on TechBio, which included investors, startups, bankers, NHS representatives, and a bioethicist. This diverse mix of participants led to a rich and engaging discussion. These takeaways underscore why we at Angelini Ventures are passionate about staying at the forefront of health innovation. Are you part of the health innovation ecosystem? Let's connect and drive meaningful innovation in healthcare together! #siftedsummit #startupcommunity #startupconference

    • Nessuna descrizione alternativa per questa immagine
    • Nessuna descrizione alternativa per questa immagine
    • Nessuna descrizione alternativa per questa immagine
  • Visualizza la pagina dell’organizzazione di Angelini Ventures, immagine

    7.761 follower

    What an incredible experience at last week's Italian Tech Week in Turin! The event brought together international speakers and guests who offered a glimpse into the major trends shaping our world. As part of the official side events, Angelini Ventures and Exceptional Ventures had the pleasure of hosting a unique networking lunch for the most innovative minds in health, wellness, and longevity. The response was overwhelming: we welcomed over 100 participants, with many more on the waiting list. We extend our sincere thanks to all who attended and invite those who couldn't join us to stay tuned for our upcoming events. A special shout-out to Exceptional Ventures Paolo Pio Anna Fortuny-Gomez, PhD Michella Botto Andrade for being fantastic partners in co-organizing this event and thank you for having fun along the way!

    • Nessuna descrizione alternativa per questa immagine
    • Nessuna descrizione alternativa per questa immagine
    • Nessuna descrizione alternativa per questa immagine

Pagine affiliate

Pagine simili

Sfoglia le offerte di lavoro